November 12-14, 2019 — Shanghai, China
Event: ChinaTrials 12
Topic: Taking Rare Diseases to the Next Level in China: Overcoming the Current Challenges
China has made a significant step in formalizing rare diseases with an initial list of 121 diseases and providing allowance for expedited review, clinical trial reduction and waivers. Even with the excitement of this nascent segment, many operational challenges remain, such as patient recruitment, payment and access, and there are questions about how much further the landscape can improve.
Helen Chen, Managing Partner, L.E.K. Consulting
- Paul Dai, Head of Clinical Operations – Asia, Takeda Pharmaceuticals
- Kevin Huang, Founder & President, China Organization of Rare Diseases
- Alan Yan, Chief Executive Officer, Sperogenix
- Gloria Wang, Chief Medical Officer – Oncology, Genscience
Thursday, November 14, 2019
JW Marriott Hotel Shanghai at Tomorrow Square
Time: 10:30-11:35 a.m.
About Helen Chen
Helen Chen is a Greater China Managing Partner of L.E.K. based in Shanghai. She was a member of L.E.K.’s Global Leadership Team from 2012 to 2016. Helen is also head of L.E.K.’s China and Asia Biopharmaceuticals & Life Sciences practice and a Director of the firm’s Asia-Pacific Life Sciences Centre of Excellence. She has extensive case work and industry experience covering the full biopharmaceutical and medical devices value chain.
Helen has 30 years of consulting and industry experience in the U.S. and Asia markets and has resided in China since 2000. She helps companies expand their presence in China and leverages China’s resources to improve their global businesses. She is a frequent speaker and author on the opportunities and issues in China’s Healthcare and Life Sciences sectors.
Now in its 12th year, ChinaTrials is the premier industry-focused clinical development event designed specifically for director-level and above executives with interest in China and North Asia development to gather together solve the industry’s current challenges. Attendees can learn from over 75 carefully selected speakers who are running hundreds of trials in China and North Asia for the world’s leading pharmaceutical, biotech and medical device companies.
About L.E.K. Consulting
L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. We are uncompromising in our approach to helping clients consistently make better decisions, deliver improved business performance and create greater shareholder returns. The firm advises and supports global companies that are leaders in their industries — including the largest private- and public-sector organizations, private equity firms, and emerging entrepreneurial businesses. Founded in 1983, L.E.K. employs more than 1,400 professionals across the Americas, Asia-Pacific and Europe. For more information, go to www.lek.com.